We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Study Combining Brain MRI Findings and Latest RNA Sequencing Technology to Identify Drugs for Preventing Post-COVID Cognitive Impairment

By HospiMedica International staff writers
Posted on 07 Sep 2021
Print article
Image: Study Combining Brain MRI Findings and Latest RNA Sequencing Technology to Identify Drugs for Preventing Post-COVID Cognitive Impairment (Photo courtesy of John Emerson)
Image: Study Combining Brain MRI Findings and Latest RNA Sequencing Technology to Identify Drugs for Preventing Post-COVID Cognitive Impairment (Photo courtesy of John Emerson)
A new study will examine how COVID-19 is affecting individuals in a number of cognitive-related areas, including memory loss, “brain fog,” and dementia.

Scientists at Rutgers University (New Brunswick, NJ, USA) are spearheading the characterization of cognitive impairment following mild-to-moderate COVID-19. The team will assess each person’s cognition, mood, and sleep patterns to identify potential causes of brain fog and compare their brain MRI findings with biochemical signatures of neuroinflammation. They will analyze microglial cells - critically important immune cells in the brain - from individuals who have had COVID-19 to determine whether those cells can be used to predict the persistence of post-COVID cognitive impairment (PCCI). This will allow researchers to begin to generate new hypotheses on why these cells may dysfunction in COVID-19 and PCCI, what the shared inflammatory mechanisms are between PCCI and Alzheimer’s disease, and whether FDA-approved drugs can be repurposed to prevent the onset of PCCI or improve its outcomes

“Many people who recover from mild or moderate COVID-19 notice slowed thinking or memory loss, and this motivated us to leverage our experience in studying cognitive issues related to Alzheimer’s disease, multiple sclerosis, and HIV to examine this phenomenon,” said Dr. William T. Hu, associate professor and chief of cognitive neurology at Rutgers Robert Wood Johnson Medical School and the Institute for Health, Health Care Policy, and Aging Research, who is leading the study.

“We have found neuroinflammation is a common theme across many brain disorders, but not all neuroinflammation is the same,” he noted. “We developed a roadmap to study the protein and cellular changes involved in worsening - as well as alleviating - symptoms of brain fog. In addition, we are using the latest RNA sequencing technology to understand how inflammatory cells ‘misbehave’ to cause memory/thinking dysfunction in long COVID.”

Related Links:
Rutgers University

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Thoracolumbar & Sacropelvic System
Ennovate TLSP
New
Sling
GoComfort

Print article

Channels

Critical Care

view channel
Image: A mechanosensing-based approach offers a potential path to the treatment for cardiac fibrosis (Photo courtesy of Adobe Stock)

Mechanosensing-Based Approach Offers Promising Strategy to Treat Cardiovascular Fibrosis

Cardiac fibrosis, which involves the stiffening and scarring of heart tissue, is a fundamental feature of nearly every type of heart disease, from acute ischemic injuries to genetic cardiomyopathies.... Read more

Surgical Techniques

view channel
Image: Bioprinting synthetic vasculature could dramatically change how cardiovascular diseases are treated (Dell, A.C., Maresca, J., Davis, B.A. et al.; doi.org/10.1038/s41598-025-93276-y)

Bioprinted Aortas Offer New Hope for Vascular Repair

Current treatment options for severe cardiovascular diseases include using grafts made from a patient's own tissue (autologous) or synthetic materials. However, autologous grafts require invasive surgery... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more